Sanofi (SNY)

48.68
1.19 2.51
NASDAQ : Health Technology
Prev Close 47.49
Open 48.01
Day Low/High 47.96 / 49.12
52 Wk Low/High 37.62 / 51.84
Volume 1.76M
Avg Volume 2.74M
Exchange NASDAQ
Shares Outstanding 2.51B
Market Cap 119.39B
EPS 1.30
P/E Ratio 25.53
Div & Yield 1.17 (2.57%)
Government Shutdown and Everything Else You Need to Know Monday Morning

Government Shutdown and Everything Else You Need to Know Monday Morning

So what does a government shutdown mean for today's trading? Here's what you need to know before Monday's opening bell.

Winners and Losers in a Temporary French Tax Revolution

Winners and Losers in a Temporary French Tax Revolution

Some French companies will get a temporary windfall, but others will need to pay more tax.

These 16 Stocks Look Ready to Reverse

These 16 Stocks Look Ready to Reverse

Tesla and General Motors are among this week's names showing reversal patterns.

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Sanofi, Shell and Credit Suisse -- Earnings Round-Up

Investors keep an eye on another busy slate of earnings.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Robert Herjavec Predicts New Legislation in Response to the Equifax Hack

Shark Tank's Robert Herjavec on why the Equifax hack is different from others cyber attacks.

Biotech Mailbag: Buy Dip in T2 Biosystems?

Biotech Mailbag: Buy Dip in T2 Biosystems?

Plus, what's going on with Lexicon Pharmaceuticals?

Sanofi Has Good Potential Upside

Sanofi Has Good Potential Upside

I would buy strength above $50 and $51 in Sanofi.

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Leaves Along With a Sanofi Director, So Let's Speculate About a Possible Deal

Sarepta CEO Ed Kaye said he's stepping down.

HSBC Security Downgrades Sanofi

HSBC Security Downgrades Sanofi

The stock was trading slightly lower this afternoon.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

Sanofi to Pay for Drug Overcharges

Sanofi to Pay for Drug Overcharges

Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

15 Remakes and Sequels Coming to the Silver Screen in 2017

15 Remakes and Sequels Coming to the Silver Screen in 2017

Hollywood's lack of originality shines through with 15 remakes and sequels this year.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Sanofi's Base Pattern Should Make Investors Happy

Sanofi's Base Pattern Should Make Investors Happy

SNY has become much stronger since late October; buy here and above $44.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

My Takeaways and Observations

The Chart of the Day demonstrates the widening schism between the real economy and stock prices.  The issuance of negative-yielding European corporate debt by Henkel, Deutsche Bahn and Sanofi are the definition of insanity. Euro bond prices are in t...

Tell Me Something I Don't Know

Regular readers of my diary know that I sometimes post something that replicates the theme of the Tell Me Something I Don't Know segment on MSNBC's Hardball With Chris Matthews. So ... "Tell me something I don't know, Dougie." OK, here goes: Henkel ...